Prostate cancer biomarkers
2010 (English)Patent (Other (popular science, discussion, etc.))
The present disclosure relates to a method of determining whether a mammalian subject belongs to a first or a second group of subjects, wherein the risk of having a prostate cancer, such as an aggressive prostate cancer, is higher in the first group than in the second group. The method comprises the steps of: a) evaluating an amount of unglycosylated CNDP1 protein in a sample derived from blood, semen or urine from the subject and determining a sample value corresponding to the evaluated amount; b) comparing the sample value with a predetermined reference value; and if the sample value is lower than or equal to the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is higher than the reference value, c2) concluding that the subject belongs to the second group. Further, the present disclosure relates to a similar method based on the protein HCRTR1 as well as corresponding uses and means useful when carrying out the methods.
Place, publisher, year, edition, pages
IdentifiersURN: urn:nbn:se:kth:diva-84255OAI: oai:DiVA.org:kth-84255DiVA: diva2:499251
QS 20152012-02-132012-02-132015-01-19Bibliographically approved